ECSP045148A - Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer - Google Patents

Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer

Info

Publication number
ECSP045148A
ECSP045148A EC2004005148A ECSP045148A ECSP045148A EC SP045148 A ECSP045148 A EC SP045148A EC 2004005148 A EC2004005148 A EC 2004005148A EC SP045148 A ECSP045148 A EC SP045148A EC SP045148 A ECSP045148 A EC SP045148A
Authority
EC
Ecuador
Prior art keywords
methyl
acetamide
methylpiridin
iloxi
metoxi
Prior art date
Application number
EC2004005148A
Other languages
English (en)
Inventor
John Charles Kath
Daniel Tyler Richter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP045148A publication Critical patent/ECSP045148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a las sales succinato y malonato de E-2-metoxi-N-(3-{4-[3-metil-4-(6-metil-piridin-3-iloxi) fenilamino]quinazolina-6-il}alil)-acetamida de la siguiente fórmula I. Más particularmente, la presente invención se refiere a las sales sesquisuccinato y dimalonato de fórmula I. La invención se refiere también a composiciones farmacéuticas que contienen las sales succinato y malonato de fórmula I. La invención se refiere además a procedimientos de tratamiento de enfermedades hiperproliferativas tales como los cánceres en mamíferos, especialmente en seres humanos, mediante la administración de las sales anteriores y a procedimientos de preparación de las sales anteriores.
EC2004005148A 2001-12-12 2004-06-11 Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer ECSP045148A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
ECSP045148A true ECSP045148A (es) 2004-07-23

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005148A ECSP045148A (es) 2001-12-12 2004-06-11 Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer

Country Status (34)

Country Link
US (1) US6844349B2 (es)
EP (1) EP1456199A1 (es)
JP (1) JP4202926B2 (es)
KR (1) KR20040065259A (es)
CN (1) CN1608062A (es)
AP (1) AP2004003059A0 (es)
AR (1) AR037772A1 (es)
AU (1) AU2002366581A1 (es)
BR (1) BR0214876A (es)
CA (1) CA2469889A1 (es)
DO (1) DOP2002000544A (es)
EA (1) EA007412B1 (es)
EC (1) ECSP045148A (es)
GE (1) GEP20063872B (es)
GT (1) GT200200272A (es)
HR (1) HRP20040530A2 (es)
HU (1) HUP0402662A2 (es)
IL (1) IL161915A0 (es)
IS (1) IS7227A (es)
MA (1) MA27095A1 (es)
MX (1) MXPA04005678A (es)
NO (1) NO20042925L (es)
NZ (1) NZ532436A (es)
OA (1) OA12735A (es)
PA (1) PA8561401A1 (es)
PE (1) PE20030716A1 (es)
PL (1) PL370858A1 (es)
RS (1) RS46404A (es)
TN (1) TNSN04112A1 (es)
TW (1) TW200301103A (es)
UA (1) UA75482C2 (es)
UY (1) UY27572A1 (es)
WO (1) WO2003050108A1 (es)
ZA (1) ZA200402995B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
RU2317295C1 (ru) * 2003-10-27 2008-02-20 Мерк Энд Ко., Инк. Соль антагониста ccr-2
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
ATE534377T1 (de) * 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CN101611029B (zh) * 2006-12-21 2014-09-10 辉瑞产品公司 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
US20230286998A1 (en) * 2020-07-06 2023-09-14 Kissei Pharmaceutical Co., Ltd. Succinate salts of octahydrothienoquinoline compound and crystals thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物

Also Published As

Publication number Publication date
IS7227A (is) 2004-04-19
AU2002366581A1 (en) 2003-06-23
KR20040065259A (ko) 2004-07-21
NZ532436A (en) 2006-01-27
WO2003050108A8 (en) 2003-12-18
PA8561401A1 (es) 2005-02-04
IL161915A0 (en) 2005-11-20
TNSN04112A1 (fr) 2006-06-01
MA27095A1 (fr) 2004-12-20
EA200400674A1 (ru) 2004-10-28
NO20042925L (no) 2004-09-07
UY27572A1 (es) 2003-07-31
PL370858A1 (en) 2005-05-30
PE20030716A1 (es) 2003-08-29
MXPA04005678A (es) 2004-12-06
HRP20040530A2 (en) 2004-10-31
WO2003050108A1 (en) 2003-06-19
OA12735A (en) 2006-06-29
CN1608062A (zh) 2005-04-20
UA75482C2 (en) 2006-04-17
RS46404A (sr) 2006-10-27
GEP20063872B (en) 2006-07-10
US20030158217A1 (en) 2003-08-21
JP4202926B2 (ja) 2008-12-24
US6844349B2 (en) 2005-01-18
JP2005511744A (ja) 2005-04-28
HUP0402662A2 (hu) 2005-05-30
DOP2002000544A (es) 2003-06-16
EA007412B1 (ru) 2006-10-27
EP1456199A1 (en) 2004-09-15
CA2469889A1 (en) 2003-06-19
AR037772A1 (es) 2004-12-01
BR0214876A (pt) 2004-12-28
AP2004003059A0 (en) 2004-06-30
ZA200402995B (en) 2005-04-20
TW200301103A (en) 2003-07-01
GT200200272A (es) 2003-12-12

Similar Documents

Publication Publication Date Title
AR037772A1 (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il]alil)acetamida y procedimiento de produccion
UY27740A1 (es) Nuevos compuestos
ECSP056019A (es) 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune
PA8551001A1 (es) Nuevos compuestos
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY28510A1 (es) Compuestos quimicos
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
UY27592A1 (es) Nuevo uso
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY28150A1 (es) Agentes terapeuticos
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
SE0100569D0 (sv) New compounds
UY27593A1 (es) Nuevos compuestos
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
UY28366A1 (es) Compuestos químicos
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios